vTv Therapeutics (NASDAQ:VTVT) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report released on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $67.00 price target on the biotechnology company’s stock.

Other research analysts have also issued research reports about the stock. Cowen assumed coverage on shares of vTv Therapeutics in a report on Monday. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. BTIG Research started coverage on shares of vTv Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.33.

vTv Therapeutics Trading Down 1.7%

Shares of VTVT opened at $41.99 on Monday. vTv Therapeutics has a twelve month low of $13.20 and a twelve month high of $44.00. The firm has a market capitalization of $165.44 million, a P/E ratio of -12.65 and a beta of 0.48. The stock’s fifty day simple moving average is $31.78 and its 200 day simple moving average is $22.91.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Institutional Trading of vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP increased its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned about 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.